Tamsulosin + Dutasteride Pharmasyntez treats and manages the symptoms of benign prostatic hyperplasia by combining two complementary ingredients. The product's unique presentation consists of a soft gelatin capsule enclosed in a hard gelatin capsule, allowing the simultaneous administration of two distinct components.

The medicine is indicated to treat and prevent progression of benign prostatic hyperplasia by reducing its size, getting rid of its symptoms, increasing urine flow rate, lowering the risk of acute urinary retention, and preventing the need for surgery.

Yevgeny Orachevsky, CEO of Pharmasyntez JSC, spoke about the new medication's entry into the public domain:

“We are pleased to announce the release of our new medicine, a combination therapy of Dutasteride and Tamsulosin. Patients with benign prostatic hyperplasia will live much better lives thanks to this medication, which effectively relieves symptoms and lowers the chance of complications. The novelty's reasonable price is another key component. The most convenient way for patients to take the combined medication is in a single capsule that contains both of the initially distinct ingredients. We are certain that this will improve quality of life and be a significant advancement in the treatment of this prevalent male pathology”.